Pulse Biosciences, Inc · NASDAQ:PLSE
Pulse Biosciences — Investor Presentation (January 2026)
17 slides from Pulse Biosciences's investor presentation, Jan 14, 2026
Slide 1: Corporate Overview January 2026
D Pulse Biosciences’ Corporate Overview January 2026
Slide 2: Forward Looking Statements
Forward Looking Statements {D) Pulse Biosciences: Al statements in this presentation that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company's Nanosecond Pulsed Field Ablation (nsPFA) technology and nPulse” System
Slide 3: Our Mission
Our Mission To build a thriving viable company by providing revolutionary and life-changing therapy for multiple diseases deploying our next-generation Nanosecond Pulsed Field Ablation technology. Our Strategy Each segment will deliver optimized development time and patient-first solutions through e
Slide 4: Experienced Technologists, Operators and Clinicians
Experienced Technologists, Operators and Clinicians From Proven Leadership Team J Darrin Uecker Jon Skinner hiet Financial Orfice Renowned Scientific Expertise a Dr. NivAd fa Dr. Gan Dunnington Dr. David Kenigsberg fs 1 hief Medical Officer, BE Chief Medical Officer Cardiac Su rdiac Su Di Elec ol Es
Slide 5: Financial Snapshot
Financial Snapshot - Strong balance sheet as of 12/31/2025 ~ Cash and cash equivalents balance of ~$81 mm (unaudited) - No debt ~ Cash burn of approximately $36mm in 2024 ~ Cash burn increasing: Strategic Capital to support significant expansion opportunities ($13.0mm of cash used in operating activ
Slide 6: Pulse Biosciences' nPulse Platform
Pulse Biosciences’ nPulse Platform to Unlocks >$6B >$16B in first 3 target markets global including US. Addressable Gtobat ‘Annual Market Potontial Market Thyroid Application $1 3B" $2. 8B" in Soft Tissue Ablation Cardiac Surgery $1 .8B” $6.0B” EP Catheter $3.0B' $8.0B° Pulse will create, expand, an
Slide 7: The Nanosecond PFA Advantage — A Novel Ablation Mechanism
The Nanosecond PFA Advantage — A Novel Ablation Mechanism Amore energy-efficient ablation mechanism, enabling larger, faster, and safer ablations Thermal - High Thermal Energy + Point to point ablation + Destroys all tissue + Thermal spread risk {D) Pulse Biosciences: First Gen PFA ~ Long-duration w
Slide 8: Pioneering nPulse Technology
Pioneering nPulse™ Technology PATENT PORTFOLIO Creating wide and deep IP portfolio to own the Nanosecond PFA space Covering nPulse energy, systems, applications, and methods +77 Issued pater Pending patent ‘owned & applications ) Pulse Biosciences:
Slide 9: EP Market Opportunity
EP Market Opportunity $3.0B° snes AF Ablation Global Atrial Market growing at Fibrillation (AF) 10-15% Al Drivers for Pulse in the EP AF Ablation Market CAGR? all + Drop-in workflow replacement + Speed + efficiency over 1st gen PFA devices - Enhanced lesion quality + Elevated safety U.S. patients nP
Slide 10: nsPFA Unlocks New Potential in EP
nsPFA Unlocks New Potential in EP 2 g \y LESION * NANOPULSE-AF IDE QUALITY SPEED WORKFLOW EFFICACY approval +Single + Fewer, faster + Map and ablate~ Durability circumferential applications single catheter eae » Expect to commence IDE lesion = . i enrollment in Q1 2026 no rotation Total VI speed sei
Slide 11: Surgical Cardiac Ablation Market Opportunity
Surgical Cardiac Ablation Market Opportunity Drivers for Pulse in the Surgical Cardiac Ablation Market + 80,000+ annual U.S. patients with pre-operative AF —~30% treated + Pulse expects to be first PFA solution to market + Existing market is RF technology ~ Obvious limitations nPulse™ technology exp
Slide 12: nsPFA Unlocks New Potential in Surgical AF Ablation
nsPFA Unlocks New Potential in Surgical AF Ablation + NANOCLAMP AF Pivotal Study approved and enrolling a) Ge + Treated 44 patients in EU o. © feasibility study LESION . QUALITY SPEED WORKFLOW EFFICACY . Presented tate breaking esta + Transmural ‘Application speed Seamless. + Durability Meeting (Oct
Slide 13: Benign Thyroid Market Opportunity
Benign Thyroid Market Opportunity BIN patients diagnosed in U.S. ~250k345 Drivers for Pulse in the U.S. Addressable Annual Market Benign Thyroid Market + Thyroid-sparing procedure ~150k ~100k ! P BP Benign Enter “Watchful, + Nonsurgical intervention thyroidectomies Waiting” + Potential to eliminate
Slide 14: nsPFA Unlocks New Potential in Soft Tissue Ablation
nsPFA Unlocks New Potential in Soft Tissue Ablation CB. o LESION QUALITY SPEED WORKFLOW sTrue non- +8 sec. ablation + Sate, fast and thermal MOA ——— efficient OR + Rapid, natural Pintkceeceneeya| (ikiaemennes delivery + Conscious Sedation for maximum patient comfort a + Multi-center clinical study (
Slide 15: Rapid Progress: 2025 Achievements and 2026 Plans
Rapid Progress: 2025 Achievements and 2026 Plans 2025 Plans and 2026 Momentum and Accomplishments Intentions + Generating Data + Clear safety, speed and workflow evidence + Efficacy evidence — Presenting at AF Symposium + IDE approved — enroll in 2026 Cardiac Surgery + Generating Data + Significant
Slide 16: Summary
Summary Novel nPulse™ Energy » Unique MOA * Patent protected * Nonthermal Target Market Values » +$6B U.S. annual addressable market * Create, expand, upend {D) Pulse Biosciences: IP +250 Issued +180 Pending * Pulse owns the Nanosecond PFA Space Portfolio of future indications * Multiple clinical pr
Slide 17: Citations
Citations 1) Dataon fle, Thyroldectomy WW Procedure Data provided byiData 2) hitossmm.ncbinim nih gov/ame/artctes/PMCE215427/ 2) Fine:Needte Aspiration ofthe Thyroid Giandhrtps://wmwneb.nim sh gov/books/NBK2ESS4Ar © OMS- htt on ddatabasolviewled. ssp edld38968Aer~4 ©) CDC--hitos//seer.cancer.gov/sta
Pulse Biosciences — Investor Presentation (January 2026) on 6ix